Abstract #2763

Early detection of recurrent prostate cancer with 18F-Fluciclovine PET/MRI

Kirsten Margrete Selnæs^1,2, Mattijs Elschot¹, Brage Krüger-Stokke^1,3, Håkon Johansen⁴, May-Britt Tessem¹, Siver Andreas Moestue^1,2, Arne Solberg⁵, Helena Bertilsson^6,7, and Tone Frost Bathen^1,2

¹Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Trondheim, Norway, ²St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ³Department of Radiology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁴Department of Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁵Clinic of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁶Department of Urology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ⁷Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway

Prostate cancer patients with biochemical relapse (rising PSA) after initial treatment are a diagnostic challenge. Simultaneous PET/MRI combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in a single imaging session. The aim of this exploratory study is to evaluate detection rate of simultaneous 18F-Fluciclovine PET/MRI for recurrent prostate cancer. The overall detection rate in an initial cohort of 16 patients was 43.8% for combined 18F-Fluciclovine PET/MR. Combined 18F-Fluciclovine PET/MR can detect areas suspicious for prostate cancer recurrence even in patients with very low PSA levels.

This abstract and the presentation materials are available to members only; a login is required.

Join Here